Multivariate analysis of baseline parameters as well as of percentage SFLC reduction from baseline to levels obtained prior to cycle 2 of induction therapy and before transplantation, associated with event-free and overall survival, excluding subjects with normal SFLC baseline levels (kappa ≤ 1.93; lambda ≤ 2.64)
| Variable . | n/N (%) . | HR (95% CI) . | P . |
|---|---|---|---|
| Overall survival from cycle 2 | |||
| Top tertile of SFLC % reduction, cycle 2 | 93/256 (36) | 2.56 (1.12,5.83) | .025 |
| LDH greater than 190 U/L | 69/256 (27) | 2.91 (1.30,6.51) | .009 |
| Cytogenetic abnormalities | 85/256 (33) | 4.56 (1.87,11.09) | <.001 |
| Event-free survival from cycle 2 | |||
| Top tertile of SFLC % reduction, cycle 2 | 93/256 (36) | 2.36 (1.16,4.81) | .018 |
| LDH greater than 190 U/L | 69/256 (27) | 2.11 (1.04,4.28) | .038 |
| Cytogenetic abnormalities | 85/256 (33) | 3.31 (1.60,6.85) | .001 |
| Overall survival from first transplant | |||
| Top tertile of SFLC % reduction, cycle 2 | 91/249 (37) | 2.25 (0.94,5.35) | .067 |
| LDH greater than 190 U/L | 65/249 (26) | 2.59 (1.10,6.09) | .029 |
| Cytogenetic abnormalities | 83/249 (33) | 4.50 (1.84,11.00) | <.001 |
| Event-free survival from first transplant | |||
| Top tertile of SFLC % reduction, transplant 1 | 90/248 (36) | 2.09 (0.98,4.44) | .056 |
| LDH greater than 190 U/L | 64/248 (26) | 1.81 (0.85,3.88) | .125 |
| Cytogenetic abnormalities | 82/248 (33) | 3.14 (1.50,6.57) | .002 |
| Variable . | n/N (%) . | HR (95% CI) . | P . |
|---|---|---|---|
| Overall survival from cycle 2 | |||
| Top tertile of SFLC % reduction, cycle 2 | 93/256 (36) | 2.56 (1.12,5.83) | .025 |
| LDH greater than 190 U/L | 69/256 (27) | 2.91 (1.30,6.51) | .009 |
| Cytogenetic abnormalities | 85/256 (33) | 4.56 (1.87,11.09) | <.001 |
| Event-free survival from cycle 2 | |||
| Top tertile of SFLC % reduction, cycle 2 | 93/256 (36) | 2.36 (1.16,4.81) | .018 |
| LDH greater than 190 U/L | 69/256 (27) | 2.11 (1.04,4.28) | .038 |
| Cytogenetic abnormalities | 85/256 (33) | 3.31 (1.60,6.85) | .001 |
| Overall survival from first transplant | |||
| Top tertile of SFLC % reduction, cycle 2 | 91/249 (37) | 2.25 (0.94,5.35) | .067 |
| LDH greater than 190 U/L | 65/249 (26) | 2.59 (1.10,6.09) | .029 |
| Cytogenetic abnormalities | 83/249 (33) | 4.50 (1.84,11.00) | <.001 |
| Event-free survival from first transplant | |||
| Top tertile of SFLC % reduction, transplant 1 | 90/248 (36) | 2.09 (0.98,4.44) | .056 |
| LDH greater than 190 U/L | 64/248 (26) | 1.81 (0.85,3.88) | .125 |
| Cytogenetic abnormalities | 82/248 (33) | 3.14 (1.50,6.57) | .002 |
Multivariate model uses stepwise selection with entry level 0.1 and variable remains if it meets the .05 level. P-value is from the Wald chi-square test in Cox regression HR indicates hazard ratio; 95% CI, 95% confidence interval; and NS, not significant.